NanoViricides,

NanoViricides, R&D per Employee

The R&D Spending per Employee of NanoViricides, (NNVC) as of Oct 20, 2026 is 672.52 B USD. In the previous year, R&D Spending per Employee was 792,728.71 USD — a change of 84.84 M% (higher).

R&D per Employee

672.52 BUSD

YoY

84.84 M%

Last updated:

R&D Spending per Employee of NanoViricides, is 2026 672.52 B USD. R&D Spending per Employee of NanoViricides, was 2025 792,728.71 USD. It decreases by 84.84 M% higher compared to the previous year.

The NanoViricides, R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
845,960.00 USD
Jan 1, 2020
670,789.14 USD
Jan 1, 2021
873,505.86 USD
Jan 1, 2022
826,408.86 USD
Jan 1, 2023
913,202.00 USD
Jan 1, 2024
776,756.71 USD
Jan 1, 2025
792,728.71 USD
Jan 1, 2026
672.52 B USD
The NanoViricides, R&D per Employee history
YEARR&D per EmployeeYoY
672.52 BUSD+84.84 M%
792,728.71USD+2.06%
776,756.71USD-14.94%
913,202.00USD+10.50%
826,408.86USD-5.39%
873,505.86USD+30.22%
670,789.14USD-20.71%
845,960.00USD+22.68%
689,548.57USD-12.74%
790,244.00USD+10.00%
718,424.29USD+37.39%
522,903.14USD-28.67%
733,074.71USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NanoViricides, Stock analysis

What does NanoViricides, do? NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. The company's unique technology is based on nanoparticles that specifically target and destroy virus cells. The company was founded in 2005 by Farooq Ansari, a former top manager at Pfizer. Together with his team, he quickly recognized the potential of nanotechnology in combating diseases and began developing various products based on this technology. NanoViricides Inc.'s business model is based on the development and commercialization of nanoparticle-based therapeutics in the global health market. The company works closely with leading research and development institutions to expand knowledge and technology in this field. NanoViricides Inc. has several product divisions specializing in combating different virus infections. The main divisions are: - FluCide: Focuses on the development of therapeutics for the treatment of influenza infections. Flu is one of the most widespread virus infections worldwide and can lead to serious complications such as pneumonia. - HerpeCide: Focuses on the development of therapeutics for the treatment of herpesvirus infections, including genital herpes, shingles, and chickenpox. - HIVCide: Focuses on the development of therapeutics for the treatment of HIV infections, aiming to develop a safer and more effective cure for HIV. - RabiCide: Focuses on the development of therapeutics for the treatment of rabies infections. - CoronaCide: Focuses on the development of therapeutics for the treatment of coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. NanoViricides Inc. has a range of products in various stages of development and research, with some already in clinical studies. The company continuously strives to improve its products and expand its research and development efforts. In summary, NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for the treatment of virus infections. It utilizes a unique technology based on nanoparticles to directly combat viruses at the cellular level. With multiple product divisions and a strong team of researchers and developers, NanoViricides Inc. is continuously working to improve the health of patients worldwide. The answer is: NanoViricides Inc. is a biopharmaceutical company specializing in the development of therapeutics for virus infections using nanoparticle-based technology. NanoViricides, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NanoViricides, stock

R&D Spending per Employee of NanoViricides, is 672.52 B USD in 2026.

R&D Spending per Employee of NanoViricides, changed from 792,728.71 USD to 672.52 B USD, representing a 84.84 M% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee NanoViricides, since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's NanoViricides, historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — NanoViricides,

All Key Metrics — NanoViricides,